Analyst firms · Mizuho · RLMD

Mizuho RLMD price target and rating history

Relmada Therapeutics Inc. (RLMD) · Health Care

Mizuho rates Relmada Therapeutics Inc. (RLMD) Outperform with a $10 price target, as of its latest action on Nov 19, 2025. It has published 3 rating actions on RLMD since November 2021, including 1 upgrade and 1 downgrade. Across 4 firms with a RLMD price target in the last 12 months, the median target is $12.

Current rating
Outperform
Price target
$10
Median target, all firms
$12
Actions on RLMD
3

Mizuho price target on RLMD

$50$26$120222023202420252026
Mizuho price target on RLMD, each point a stated target, November 2021 to November 2025.

Every Mizuho rating on RLMD

How other firms rate RLMD

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
H.C. WainwrightBuy$12Jun 18, 2026
Piper SandlerOverweight$12Mar 24, 2026
Leerink PartnersOutperform$8Jan 23, 2026
JefferiesBuy$69Dec 22, 2025

Questions about Mizuho and RLMD

What is Mizuho's price target for RLMD?
Mizuho's latest stated price target for Relmada Therapeutics Inc. (RLMD) is $10, from its action on Nov 19, 2025.
What is Mizuho's rating on RLMD?
Mizuho rates RLMD Outperform, a bullish rating, as of Nov 19, 2025.
When did Mizuho last change its view on RLMD?
On Nov 19, 2025, Mizuho upgrades to Outperform from Neutral, price target $10.
How does Mizuho's RLMD target compare with other analysts?
Across 4 firms with a RLMD price target in the last 12 months, the median target is $12.

All Mizuho ratingsRLMD news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.